Aldehyde dehydrogenase 1A1 confers erlotinib resistance via facilitating the reactive oxygen species-reactive carbonyl species metabolic pathway in lung adenocarcinomas

Background: Acquired resistance to epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) such as erlotinib is a major challenge to achieve an overall clinical benefit of the targeted therapy. Recently, aldehyde dehydrogenase 1 (ALDH1) induction has been found to render lung adeno...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Theranostics
Huvudupphovsmän: Lei, Hui-Min, Zhang, Ke-Ren, Wang, Cong Hui, Wang, Yang, Zhuang, Guang-Lei, Lu, Li-Ming, Zhang, Jian, Shen, Ying, Chen, Hong-Zhuan, Zhu, Liang
Materialtyp: Artigo
Språk:Inglês
Publicerad: Ivyspring International Publisher 2019
Ämnen:
Research Paper
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC6831290/
https://ncbi.nlm.nih.gov/pubmed/31695757
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.35729
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk